Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2014 (2014), Article ID 802307, 5 pages
Clinical Study

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis

1MS Centre, Department of Neurology and Psychiatry, Sapienza University, Viale dell’Università, 30-00185 Rome, Italy
2Physical Therapy Unit, S. Andrea Hospital, via di Grottarossa, 1035-00189 Rome, Italy

Received 22 January 2014; Accepted 1 March 2014; Published 27 March 2014

Academic Editor: Francesco Patti

Copyright © 2014 Luca Prosperini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We report a 14-week post-marketing experience on 20 patients with multiple sclerosis (MS) who started prolonged-release (PR) oral dalfampridine 10 mg twice daily according to European Medicine Agency criteria. They underwent serial static posturography assessments and the dizziness handicap inventory (DHI) to investigate whether PR dalfampridine could impact standing balance and self-reported perception of balance. The incidence of accidental falls per person per month was also recorded throughout the study. Eight (40%) patients, who had a relevant improvement in walking speed, were defined as treatment responders. They showed a significant improvement of standing balance (with respect to pretreatment assessment) when contrasted with 12 (60%) nonresponders ( = 3.959, ). No significant changes in DHI score, as well as in its functional, physical, and emotional subscales, were found in both responders and nonresponders at the end of study (all P values are ≥0.2). Treatment response did not affect the incidence of accidental falls. Future studies based on larger sample sizes, and with longer followup, are required to confirm the beneficial effect of PR dalfampridine on standing balance.